Updates are available Correction dated 2026-02-02
Click to view Correction: https://doi.org/10.1007/s10875-026-01983-6
-
Authors
Lumry, William R.
Palumbo, Michael
Hsu, Connie
Hussain, Iftikhar
McNeil, Donald
Bridges, Tracy
Wedner, H. James
Scarupa, Mark
Mondou, Elsa
Nanaware-Kharade, Nisha
Hanna, Kim
Coll, Montse Querolt
Oliveras, Juan
-
Funding
Funding for this research was provided by:
Grifols
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 9 October 2025
First Online: 12 November 2025
Change Date: 5 December 2025
Change Type: Update
Change Details: The original version of this paper was updated to correct an error in the Figure 1 caption. The caption incorrectly described the dosing regimen for treatment-experienced patients during period 1 as daily, when it was in fact weekly.
Change Date: 2 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10875-026-01983-6
Declarations
:
: CH, IH, DM, TB, HJW and MS report no competing interests. WL reports that his institution has received research grants from CSL Behring, KalVista, Ionis, Pharvaris and Astria. WL has received consulting fees from BioCryst. CSL Behring, Astria, KalVista, Intellia, Pharvaris, Pharming and Takeda and honoraria from Pharming, CSL Behring, Takeda and Biocryst. WL has served on advisory boards for Biocryst, CSL Behring, Astria, KalVista, Intellia, Pharvaris, Pharming, Takeda and the medical advisory board of the US Hereditary Angioedema Association. MP reports serving as a speaker for CSL Behring and serving on advisory boards for Takeda. EM, NN-K, KH, MQC, and JO are employees of Grifols.
